ReviewPituitary2022
Modern imaging in Cushing's disease.
Review in Pituitary, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06701838 (Osilodrostat Therapy and 11C-methionine PET to IMprove Corticotroph Pituitary Adenoma Detection and Localisation in Patients With Cushing's Disease), which is not on this map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Osilodrostat Therapy and 11C-methionine PET to IMprove Corticotroph Pituitary Adenoma Detection and Localisation in Patients With Cushing's Disease
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it.
- MRI for Cushing Disease: A Systematic Review.AJNR. American journal of neuroradiology · 2023Pooled it
- Prospective Multicenter Evaluation of [Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2025Trial
- Functional pituitary adenoma imaging.Reviews in endocrine & metabolic disorders · 2026Review
- Clinical management challenges of Cushing's disease associated with double pituitary adenomas: four cases and literature review.Endocrine · 2026Review
- Cushing's disease across the lifespan: a case-based clinical review.Archives of endocrinology and metabolism · 2026Review
- The value ofHypertension research : official journal of the Japanese Society of Hypertension · 2026Article
- Enhanced Radiological Detection of a Corticotroph Adenoma Following Treatment With Osilodrostat.JCEM case reports · 2025Article
- A bibliometric analysis of Cushing's disease and magnetic resonance imaging: history, research hotspots, and emerging trends.Quantitative imaging in medicine and surgery · 2025Article
- Using the PET/CT radiotracer [Communications medicine · 2025Article
- Challenges and opportunities for new intraoperative optical techniques in the surgical treatment of pituitary adenomas: a review.Journal of biomedical optics · 2025Review
- 7T MRI for Cushing Disease: A Single-Institution Experience and Literature Review.AJNR. American journal of neuroradiology · 2024Review
- Back to the Future: Dynamic Contrast-Enhanced Photon-Counting Detector CT for the Detection of Pituitary Adenoma in Cushing Disease.AJNR. American journal of neuroradiology · 2024Article
- An individualized approach to the management of Cushing disease.Nature reviews. Endocrinology · 2023Review
- Development of a bespoke phantom to optimize molecular PET imaging of pituitary tumors.EJNMMI physics · 2023Article
- Continuing Challenges in the Definitive Diagnosis of Cushing's Disease: A Structured Review Focusing on Molecular Imaging and a Proposal for Diagnostic Work-Up.Journal of clinical medicine · 2023Review
- Ectopic sphenoidal ACTH-secreting adenoma revealed byBMC endocrine disorders · 2023Article
- Neuroimaging of pediatric tumors of the sellar region-A review in light of the 2021 WHO classification of tumors of the central nervous system.Frontiers in pediatrics · 2023Review
- Emerging diagnostic methods and imaging modalities in cushing's syndrome.Frontiers in endocrinology · 2023Review
- Special issue: Cushing's disease update.Pituitary · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Management of Cushing's disease is informed by dedicated imaging of the sella and parasellar regions. Although magnetic resonance imaging (MRI) remains the investigation of choice, a significant proportion (30-50%) of corticotroph tumours are so small as to render MRI indeterminate or negative when using standard clinical sequences. In this context, alternative MR protocols [e.g. 3D gradient (recalled) echo, with acquisition of volumetric data] may allow detection of tumors that have not been previously visualized. The use of hybrid molecular imaging (e.g.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.